About Us

At Alzheon, we apply a precision medicine approach utilizing our scientific knowledge and clinical expertise to make advances in the challenging field of therapeutics for Alzheimer’s and other neurological disorders. Our efforts have resulted in ALZ-801, a novel, investigational medicine with an ideal profile for Alzheimer’s patients: an oral pill with favorable safety and the ability to interfere with the amyloid pathology that leads to Alzheimer’s disease.

Our experienced team

We are a passionate team of neuroscientists, pharmacologists, medicinal chemists, clinicians and drug developers with a long and proven track record in the field of Alzheimer’s disease therapeutics. Collectively, we have led many development programs at biotech and pharmaceutical companies. Our specialized experience in the field of neurology allows Alzheon to move towards new therapeutic solutions rapidly and efficiently.

Meet our team

Our lead Phase 3-ready product candidate

ALZ-801, is an oral small molecule inhibitor of amyloid aggregation and neurotoxicity that is advancing into Phase 3 registration studies in patients with Alzheimer’s disease. Alzheon created ALZ-801 after integrating information that had been overlooked in the field: a large clinical program in Alzheimer’s patients, new understanding of therapeutic responses in patient subpopulations, and understanding of the amyloid pathology of Alzheimer’s disease – and combined it with our own new insights into the molecular mechanism of action of the compound. Our state-of-the-art clinical program with ALZ-801 applies a precision medicine approach designed with insights into the patient subpopulations most likely to respond and accurate selection of patients using objective biomarkers.

Discover ALZ-801

Other Programs

In addition to Alzheimer’s disease, we are pursuing other pipeline programs that address neurological or neurodegenerative diseases that are caused or progress based on the same pathology: neuro-toxic accumulation of amyloid. We are developing and deploying a proprietary library of compounds that bind to amyloid before it accumulates in order to avert the pathology caused by amyloid aggregation and plaques.

Explore our pipeline